Ottawa – To prevent severe RSV disease during their first RSV season, RSV monoclonal antibodies are recommended for infants born prematurely. Nirsevimab is preferred over palivizumab and should be provided to infants born at less than 37 wGA and entering, or born during, their first RSV season. Infants and children born at less than 37 wGA who do not have …